



**HAL**  
open science

## Crystallographic studies of pharmacological sites in pentameric ligand-gated ion channels

Ludovic Sauguet, Azadeh Shahsavar, Marc Delarue

► **To cite this version:**

Ludovic Sauguet, Azadeh Shahsavar, Marc Delarue. Crystallographic studies of pharmacological sites in pentameric ligand-gated ion channels. *Biochimica et Biophysica Acta (BBA) - General Subjects*, 2015, 1850 (3), pp.511-523. 10.1016/j.bbagen.2014.05.007 . pasteur-02167404

**HAL Id: pasteur-02167404**

**<https://pasteur.hal.science/pasteur-02167404v1>**

Submitted on 9 Mar 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# **CRYSTALLOGRAPHIC STUDIES OF PHARMACOLOGICAL SITES IN PENTAMERIC LIGAND-GATED ION CHANNELS**

Ludovic Sauguet (1), Azadeh Shahsavar (1,2) and Marc Delarue (1)

1. Unité de Dynamique Structurale des Macromolécules, UMR 3528 du CNRS, Institut Pasteur, 75015 Paris, France
2. Present address: Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark.

## **Overview**

- 1. Introduction**
- 2. Structure and Function of pLGICs: general considerations**
- 3. The orthosteric neurotransmitter binding site**
- 4. Modulation through allosteric sites in the ECD**
- 5. Modulation through allosteric sites in the TMD**
- 6. Conclusion and perspectives**

## Summary

### BACKGROUND

Pentameric ligand-gated ion channels (pLGICs) mediate fast chemical transmission of nerve signals in the central and peripheral nervous system. *On the functional side*, the binding of a neurotransmitter (glycine, GABA, acetylcholine or 5HT3) in the extracellular domain (ECD) causes the opening of an ionotropic pore in the transmembrane domain (TMD). In addition the response to the neurotransmitter binding can be modulated by several chemical compounds acting at topographically distinct sites. This is the reason why these receptors are the target of several classes of world-wide prescribed drugs, including general anaesthetics, smoking cessation aids, anxiolytics, anticonvulsants, muscle relaxants, hypnotics and anti-emetics. *On the structural side* recent progress has been made on the crystallization of pLGICs in its different allosteric states, especially pLGICs of bacterial origin.

### SCOPE OF REVIEW

This review focuses on the crystallographic structure of complexes of pLGICs with a number of ligands of pharmacological interest. First, we will review structural data on the orthosteric binding site, where the neurotransmitter binds. Next, we will describe modulation sites in the ECD or the TMD.

### MAJOR CONCLUSIONS

It will be highlighted how sites that had been described earlier using biochemical techniques can be rationalized using structural data. Furthermore, it will become apparent that the molecular understanding of the underlying allosteric transitions is necessary in order to shed light on the modulation mechanisms of existing drugs.

### GENERAL SIGNIFICANCE

Overall, understanding the interplay between the different modulation sites at the structural level should help the design of future drugs targeting pLGICs.

## 1. Introduction

Pentameric ligand-gated ion channels (pLGICs) constitute a large family of receptors widely expressed in multicellular animals from invertebrates to mammalian, including human, as well as in a few bacterial and archaeal species (1). They allosterically convert the binding of a neurotransmitter in their extracellular domain (ECD) to the opening of an ionotropic pore in their transmembrane domain (TMD) (Fig 1A). First discovered in vertebrates, pLGICs mediate fast chemical transmission of nerve signals in the central and peripheral nervous system. The family encompasses the anionic glycine (Gly),  $\gamma$ -amino butyric type A (GABA<sub>A</sub>) and  $\gamma$ -amino butyric type B (GABA<sub>B</sub>) receptors on one side and the cationic nicotinic acetylcholine (nACh) and serotonin (5-HT<sub>3</sub>) receptors on the other side. Dysfunction of pLGICs is associated to several disorders of the central nervous system, including hyperplexia, myasthenia gravis, epilepsy, nicotine and alcohol addiction, schizophrenia, as well as Alzheimer's and Parkinson's diseases. Over the past decades, pLGICs have been used as targets for the development of novel therapeutics against nervous-system disorders by the pharmaceutical industry (2). These receptors are the target for several classes of world-wide prescribed drugs, including general anaesthetics, smoking cessation aids, anxiolytics, anticonvulsants, muscle relaxants, hypnotics and anti-emetics. These drugs allosterically modulate pLGIC function by acting at several topographically distinct sites, distributed from the ECD to the TMD. Structural variety of these drugs and differences of their biological effects illustrate the wealth of these receptors pharmacology.

This review focuses on the recent progress made on the crystallization of pLGICs bound to a number of ligands of pharmacological interest. These receptors are not fixed structural entities but are able to undergo discrete allosteric transitions between multiple states, including basal, active and desensitized states. Agonists, antagonists, as well as positive and allosteric modulators, all select and stabilize structurally different conformations, suggesting that allosteric binding sites display multiple modes (3) (Fig 1A & 1B). This review aims to outline how recent progress on the molecular understanding of their allosteric transitions sheds light on the modulation mechanisms of existing drugs and should overall benefit to the design of future drugs.

## 2. Structure and function of pLGICs: general considerations

### 2.1. Overall structure: conservation of a common core



Recently reported full-length structures of several members of the family provided significant insights into the architecture of these receptors. Integral pLGIC structures encompass the electron microscopy structure of the *Torpedo marmorata* nAChR (4), the X-ray structures of two prokaryotic channels, derived from *Erwinia chrysanthemi* (ELIC) (5) and *Gloeobacter violaceus* (GLIC) (6, 7), and the eukaryotic glutamate-activated pLGIC from *Caenorhabditis elegans* (Glu-Cl) (8). All pLGICs share a conserved organization with five identical or homologous subunits symmetrically-arranged around a central ionic pore (Fig. 1B). Each of these subunits is composed of a N-terminal extracellular ligand-binding domain (ECD) and an ionotropic transmembrane domain (TMD). In addition to integral pLGICs, several isolated ECD and TMD structures have been solved: the water-soluble pentameric AChBP homolog (9), the ECD of  $\alpha 1$  nAChR in complex with  $\alpha$ -bungarotoxin (10),  $\alpha 7$ nAChR/AChBP chimeras (11, 12), GLIC ECD (13, 14), as well as isolated TMD of the  $\alpha 1$ nAChR (15) and  $\alpha 1$ GlyR (16). Nevertheless, the functional implications concerning ligand-activation and modulation that can be deduced from isolated domains or monomeric structures are limited because the vast majority of allosteric modulatory sites are located at the interface between adjacent subunits or close to the ECD/TMD interface.

ECD of all pLGICs are folded in a highly conserved immunoglobulin-like  $\beta$ -sandwich fold, composed of an inner and an outer  $\beta$ -sheet, stabilized through conserved hydrophobic residues (1). The connecting loops, whose length and structure vary among pLGICs, are critical for the quaternary assembly of the receptor, binding the agonist and transducing its signal to the TMD. The TMD of each protomer that compose the receptor is made of four membrane-spanning helices named M1 to M4. The M2 helices form an ionotropic transmembrane pore and are thus the most important segments of the ion conduction pathway. The M1, M3 and M4 helices face the lipid bilayer and were shown to host lipid-binding sites in GLIC (7). Similarly to the ECD, the connecting loops play a determinant role for channel function, such as the M2-M3 loop that participate actively to signal transduction (1).

## 2.2 Crystallography of pLGICs binding sites: methodological aspects

Ligand-bound pLGIC structures have provided insight on the binding-sites of several important classes of agonists, allosteric modulators and inhibitors (Table 1). These structures were obtained either by growing crystals in the presence of the molecule of interest (co-crystallization) or by soaking preformed *apo* crystals in a solution containing the molecule of interest. Other drugs, like ivermectine were added during detergent solubilisation and remained stably bound to the Glu-Cl receptor after purification and crystallization (8).

Similarly, endogenous tightly bound native lipids that were remained bound throughout the sample preparation process from the original source were also observed in the GLIC receptor (7). However, high throughput crystallography for drug discovery is not easily transferable to pLGICs because of the relatively low resolution at which their structures are usually solved. Furthermore, co-crystallization and soaking into a ligand-containing solution usually requires additional manipulations of the crystals that can affect their diffraction power. Indeed, ligand-bound structures of pLGICs were solved at resolutions ranging between 2.7 and 3.9 Å (Table 1). Assigning confidently a small ligand into the electron density is difficult at such resolutions and might lead to spurious results. This limitation can be overcome by making use of the anomalous scattering of certain atoms at or near their X-ray absorption edges to localize specifically these atoms in the electron density (Fig. 2A). This approach has been readily used in pLGICs; bromine and iodide have thus been used to identify monovalent anion-binding sites (8, 17), cesium and rubidium to identify monovalent cation-binding sites (17, 18), and barium to identify divalent cation-binding sites (19). This method can also help to localize and orientate a ligand in the electron density, when substituted with derivatized-analogues that contain an anomalous scatterer. This approach proved to be particularly useful when localizing channel blockers (18), benzodiazepines (20), as well as more labile molecules for which, the binding energy is low, like alcohols and general anaesthetics. Bromo-ethanol and bromoform have thus been used as surrogate to ethanol (21) and chloroform (21, 22), respectively (Fig. 2B).

## 2.3 Function

### 2.3.1 Gating (closed to open transition)

Available full-length structures of pLGICs solved in different conformations offered new opportunities to examine channel opening and closure at the atomic level. Indeed, GLIC (6, 7) and Glu-Cl (8) display a very similar open-pore conformation, while ELIC displays a closed pore conformation(5). Previous attempts to model the gating transition compared the GLIC or the GluCl open structures to the ELIC closed structure, assuming that ELIC is a good model for the resting form (23, 24). However, the low sequence identity between these structures does not allow disentangling sequence effects from functionally relevant conformational changes. In addition, it is not certain that ELIC represents the resting form, as there are other closed forms of the receptors known to exist, such as the desensitized form for instance (see below). Among the currently existing X-ray structures, the GLIC prokaryotic proton-gated ion channel is probably the best structural model to study allosteric transitions in

pLGICs, as its structure has been determined in 3 distinct forms. GLIC structure was initially solved at acidic pH in its open conformation (6, 7), and later in a locally-closed (LC) conformation displayed by different mutants (25, 26). The LC conformation shares most structural features with the open form but displays a closed pore as a result of a concerted bending of its M2 helices. Recently, it was demonstrated that the wild-type receptor can adopt the LC form as well and that the open and LC form can co-exist as discrete ones at acidic pH (27). This is consistent with the possibility that the LC form might represent a late intermediate in the course of activation. Most importantly, the resting-state structure of GLIC has very recently been solved at neutral pH, thereby providing the two end-points of the gating mechanism in the same pLGIC (27).

Upon activation, a marked quaternary reorganization of the ECD is observed, involving both a twist and an inward tilt motion (the inverse of a blooming motion) of each ECD monomer (Fig. 3A), reshaping the ECD-ECD interface, especially around the agonist binding site. At the tertiary level, tightening of the inner and outer  $\beta$ -sheets profoundly remodels the ECD-TMD interfaces. Extensive interactions of the ECD with the M2-M3 loop cause a revolving motion of this loop, accompanied by a concerted unbending of the M2 helices, which opens the pore. The motion of M2 helix and the M2-3 loop is stabilized by a kink of helix M1, both helices now interacting across adjacent subunits (Fig. 3A).

Interestingly, the conformation of the resting-state GLIC TMD is very different from what is observed in ELIC (Fig. 3B). In resting-state GLIC, the pore is closed due to a concerted bending of the upper part of the M2 helices of all five subunits, which detach from M3 and obstruct the pore by forming a packed bundle, along with a revolving motion of the M2-3 loop that is similar to what is observed in the LC conformation. In ELIC, helix M2 and helix M3 do not detach from each other, but remains associated (Fig. 3C). Mutagenesis and electrophysiology studies performed on GLIC are in very good agreement with the idea that the bending/unbending of M2 is a key structural determinant for gating. As expected, crosslinking M2 and M3 in their upper parts as in the open form results in a marked gain-of-function phenotype (25). Furthermore, studies that include surface cysteine accessibility method experiments (28), as well as directed spin labelling and electron paramagnetic resonance spectroscopy (29, 30), revealed that activation involves an outward translational movement of the tip of M2 helices whereas the lower part of these helices remains relatively immobile. These observations suggest that the ELIC TMD is not in its resting-state conformation. Because no significant structural change is observed following agonist binding in ELIC structure, this ELIC crystal structure might instead represent a desensitized form

(20). In any case, this data documents the important plasticity of the TMD that is often erroneously described as a rigid and optimally packed helical bundle.

### 2.3.2 Permeation: Ion transport

Abundant biochemical, biophysical and mutational data have demonstrated that the ion permeation pathway encompasses the full-length structure of pLGICs but that the transmembrane channel is the dominant determinant part of the molecule for ion permeation and selectivity (31-35). In contrast to what is observed with the highly selective potassium channels exemplified by KcsA, pLGICs have been shown to screen for charges rather than for a specific radius (36, 37). The open ion-conducting structures of GLIC and GluCl show a highly conserved architecture of the pore. In its open form, the pore is funnel-shaped, characterized by a 12 Å large diameter in the extracellular part and a 5 Å narrow constriction in the cytoplasmic part, that has been shown to host the selectivity filter portion, based on permeation, mutational and computational studies (38, 39). Consistently, in both GLIC and GluCl structures, this hydrophilic region provides favourable binding sites for cations (17, 18) and anions (8), respectively. While the molecular determinant of ion selectivity in pLGICs is abundantly documented, the molecular mechanisms of ion permeation remains poorly understood. Ion permeation implies complex mechanisms that involve protein residues, ions and water molecules, which interact together dynamically and transiently as the ions flow down the channel. This kind of description is difficult to derive from existing structures given the limited structural resolution achieved by X-ray crystallography. Recently, the 2.4 Å resolution structure of GLIC allowed a more detailed insight into ion permeation, revealing for the first time the hydration geometry in the pore of a pLGIC (17) (Fig. 4A). Two water pentagons were observed at the level of two rings of hydroxylated residues (Ser 230 and Thr 226, Ser 6' and Thr 2' in prime notation, counting from the N-terminus of M2), with one Na<sup>+</sup> ion between them. The pentagon located at position 2' is part of the hydration shell of a Na<sup>+</sup> ion, which afterwards can be accommodated further down by a ring of negatively-charged glutamate residues. In contrast, the water pentagon situated at position 6' is self-stabilized. This crystallographic description of pore hydration was complemented by molecular dynamics (MD) simulations in the hydrophobic part of the pore, where hydration cannot be studied by crystallography due to the presence of detergent molecules. In this region, the MD simulation-derived water density distribution reveal that water molecules are arranged in five layers, with two of them interacting directly with main-chain carbonyl oxygen atoms of the Ile 9' and Ala 13' rings of residues. The three remaining layers of water molecules do not

interact directly with the protein but do interact instead with the two principal layers of water molecules. This network of water molecules covers the edge of the hydrophobic half of the pore thus rendering it polar (Fig. 4A). Simulations that pulled a cation through the pore revealed that the water pentagons observed in the crystal actively contribute to ion translocation. Mutations of residue Ser 6' to Val or Gly severely impaired channel conductance, due to a local dehydration of the 2'-9' region (17). Altogether, these data suggest that ordered water molecules contribute to lower the energy barriers encountered by the permeant ion when it crosses hydrophobic constrictions that are located along the selectivity filter. Electrostatic calculations also documented the roles of residues Ser 6' and Thr 2' during permeation, suggesting that their dynamical properties could facilitate ion transport by reducing electrostatic free energy barriers encountered by the ion during its translocation. Due to the strong sequence conservation of M2 pore-lining residues, these observations might be transferable to all the pLGIC channels.

### **3. The neurotransmitter orthosteric binding site**

#### **3.1 Conserved ligand recognition in AChBPs and pLGICs**

The ligand-binding site is located at the ECD-ECD interface of the pentamer. For GLIC, the unique proton-gated channel of the family, it is clear that the proton-sensing domain is located in the ECD since a chimera construct made of the ECD of GLIC and the TMD of GlyR is functional and can be activated by protons (40). Within the whole family, the best functionally characterized orthosteric binding site is that of nAChRs. Early affinity labelling experiments followed by extensive mutagenesis experiments have located the acetylcholine (ACh) binding site at the interface between two neighbouring subunits, with the contribution of three regions from a principal subunit, named loops A, B, and C and four regions of a complementary subunit named loops D, E, F and G (41). Detailed insights into structural determinants of ligand-recognition have initially been provided by the high-resolution structures of soluble AChBPs that have been widely adopted as surrogates of the ECD of pLGICs. More than 60 X-ray structures of AChBPs have been determined in complex with a wide variety of ligands. More recently, two full-length structures of pLGICs, glutamate-bound GluCl and GABA-bound ELIC, have been solved in complex with neurotransmitters (8, 20, 42). Overall, an amazing similarity of structures emerges from comparison of the various modes of neurotransmitter binding. The primary/tertiary/quaternary amines moieties of the neurotransmitters interact with a conserved aromatic box of the

orthosteric agonist-binding site. For a recent review and a structural view of the conserved sequence motifs in the family, see (43).

### **3.2 Ligand activation in pLGICs**

While AChBP provides a successful model to decipher the molecular determinants of ligand recognition in pLGICs, it is not a suitable model for tracking the conformational transitions, which couple ligand-binding to channel activation. Indeed, all AChBP structures display the same conformation, with the notable exception of the “clamping” loop C that adapts to the size of the ligands. Loop C thus alternates between a fully contracted conformation observed for agonists, a fully extended conformation for peptide inhibitors and an intermediate conformation for non-peptide antagonists (44) (Fig. 5A). The GLIC X-ray structures, solved in their open and resting-state closed conformations, provide a molecular basis for understanding the agonist-induced opening of the channel (27). Comparing the unliganded and ligand-bound GLIC structures reveals that the orthosteric agonist-binding site is much more profoundly remodelled than in the AChBP agonist/antagonist bound structures (Fig. 5B). Rearrangement of the interface of the orthosteric pocket involves the sliding (translation) of the complementary subunit by about one interstrand distance resulting in a more extensive surface interaction between neighbouring subunits in the open form. Consequently, activation of the receptor results in a marked contraction of the orthosteric pocket. Both the amplitude and the mechanism of this expansion/contraction in GLIC differ from what is usually described in AChBP structures, especially because there is no quaternary rearrangement in the latter structures, whereas there is a profound one in GLIC (Fig. 5B).

In addition, this study also revealed a functionally important feature of the unliganded resting-state form of the receptor, which is a much larger conformational basin than in the open form (27). In contrast to the open form, the GLIC resting state structure fluctuates between an ensemble of closed conformations that differ from each other mainly at the level of the ECD. This population of receptors in a resting state could thus adapt to much more structurally diverse antagonists than the open state can bind agonists, in line with the fact that antagonists cover a much wider chemical space than agonists.

## **4. Modulation through allosteric sites in the ECD**

### **4.1 Benzodiazepines**

pLGICs are allosterically modulated by benzodiazepines, a class of widely prescribed clinical drugs that display anxiolytic, anticonvulsant, muscle relaxant and sedative-hypnotic

effects (45). Benzodiazepines have been shown to modulate ELIC with effects comparable to that seen on GABA<sub>A</sub> receptors, which are the principal target for benzodiazepines among the pLGIC family (20). Co-crystal structures of ELIC with flurazepam indicate that benzodiazepines, depending on their concentration, occupy two distinct sites in ELIC. Indeed, benzodiazepine has been shown to occupy an intrasubunit site facing the channel vestibule, as well as an intersubunit site that partially overlap agonist-binding to the orthosteric site. Mutagenesis experiments combined to electrophysiology recordings revealed that these two sites are associated with opposite modulatory effects; the intrasubunit and inter subunit sites are respectively responsible for potentiating effects at low concentration of benzodiazepines, and the inhibitory effects at higher concentrations. While the intrasubunit site appears to be novel, the intersubunit site matches with a previously identified benzodiazepine low-affinity inhibitory site in eukaryotic GABA<sub>A</sub> receptor (46).

#### **4.2 Divalent Ions modulatory site**

The modulation of pLGICs by divalent cations, such as Ca<sup>++</sup> and Zn<sup>++</sup>, is thought to play an important regulation role in a physiological context (2). For instance, millimolar concentrations of Ca<sup>++</sup> potentiate channel activation of nAChRs (47, 48) and inhibit those of 5HT3Rs (49), while Zn<sup>++</sup> can either inhibit or potentiate the agonist response, depending on its concentration and the type of pLGIC (50, 51). The successive occupation of binding sites of different affinities is thought to cause these opposing effects. Recently, divalent ions were shown to inhibit channel activation on ELIC (19). Combining a crystal structure of the receptor solved in complex with Ba<sup>++</sup> and mutagenesis experiments has identified the site responsible for divalent inhibition in ELIC. It is located at the outer rim of the ECD, at the level of the interface between subunits, but at a site topographically distinct from the agonist-binding site. This site overlaps with a Ca<sup>++</sup> modulation site identified in  $\alpha$ 7-nAChR.

#### **4.3 Other ion binding sites in GLIC**

A recent 2.4 Å structure of GLIC, combined with the systematic use of anomalous diffraction data collected on crystals soaked with Br<sup>-</sup>, Cs<sup>+</sup> and Rb<sup>+</sup> allowed the assignment of several distinct ion-binding sites in the vestibule-edge region of the ECD (17). These ion-binding sites, whose physiological implications remain to be explored, are located within highly conserved regions of the ECD, such as the Trp-X-Pro canonical motif.

In addition, two acetate-binding sites were identified in GLIC; the first one is situated



at the vestibule edge and overlaps the intra-subunit benzodiazepine-binding site identified in ELIC (20), while the second acetate binding-site is located at the interface between adjacent subunits, next to the region that hosts the agonist-orthosteric binding site in other pLGICs. The latter site is thought to be an inhibitory allosteric site that accounts for the millimolar range inhibition of acetate, and the micromolar range inhibition of caffeic acid on GLIC (52). As a conclusion, pLGIC display multiple ion modulatory sites, which are highly selective from one subtype to the other. These sites are still largely unexplored and constitute plausible targets for drug design.

## **5. Modulation through pharmacological sites in the TMD**

The TMD is the target of a wide variety of allosteric modulators including ethanol and other alcohols, general anaesthetics (GAs), lipids and open-channel pore blockers.

### **5.1 General anaesthetics and alcohols**

GA and alcohols exert many of their actions on the central nervous system by binding to and modulating pLGICs. Modulation sites for alcohols and GA have been characterized experimentally by combining photolabelling studies (53), site-directed mutagenesis and electrophysiology (54, 55). Three principal GAs and alcohols binding-sites have thus been identified within the TMD: (i) an intrasubunit site located within the M1-4 helix bundle, (ii) an intersubunit site and (iii) a channel-site situated at the extracellular end of the pore. Consistently, pLGICs crystal structures solved in complex with GA and alcohols have covered all three binding sites (Fig. 6). Propofol, desfluran and bromoform were shown to bind to an intrasubunit site in GLIC (21, 56). Ethanol, 2-bromo-ethanol and bromoform were found to bind to an inter-subunit cavity in the structure of a GLIC ethanol-sensitive variant (21). In ELIC, bromoform was recently shown to bind both in the ion channel and in an intersubunit site (22). GAs and alcohols binding to these distinct sites produce opposing effects on channel function. In GLIC, the intersubunit cavity hosts an allosteric potentiating site (21), while the intrasubunit hosts an allosteric inhibitory site (56). Furthermore, a single-mutation in the intersubunit site turns desflurane, chloroform and bromoform from inhibitors to potentiators, suggesting that their hosting sites are competing allosteric sites (21, 57). Modulation is thus the net effect of competitive binding between the intersubunit potentiating site and an intrasubunit inhibitory site. This multiple-site model of allosteric regulation is also relevant when studying mammalian pLGICs, as GA and alcohols produce opposing effects



depending on the pLGIC subtype. Indeed, they potentiate function of most inhibitory GABA<sub>A</sub>Rs and GlyRs, while they inhibit most of the excitatory nAChRs (58). These distinct binding sites will now be reviewed in the light of recent crystal structures and functional experiments.

### 5.1.1 Intrasubunit GA modulatory site

Similarly to nAChRs, GLIC is inhibited by clinically relevant concentrations of GAs (59), long chain alcohols and is weakly sensitive to potentiation by ethanol (60). Co-crystal structures of GLIC bound to propofol, desflurane (56) and bromoform (21) reveal that GAs bind to overlapping sites within a cavity located in the upper part of the TMD at the centre of the bundle of alpha-helices of each subunit (Fig. 6). This tunnel-shaped cavity is accessible from the lipid bilayer and penetrates in the interior of the subunit towards the ECD-TMD interface. The bromoform-bound GLIC structure revealed that bromoform adopts three distinct poses within the cavity, suggesting that GAs display a relatively high mobility in this cavity (21), a feature consistent with results of MD, which show that Van der Waals interactions are the main contributor to the binding energy (56). A recent study on the *T. marmorata* nAChR using a photoreactive propofol analogue and radioligand competition assays revealed for the first time a single intrasubunit propofol-binding site and suggests that the cavity of GLIC is a strong candidate for the nAChR allosteric inhibitory site (61). Yet, the molecular mechanism of inhibition induced by GAs upon binding to this intrasubunit site remains an open question as existing GLIC structures of the receptor bound to GA all display an open conformation while GAs should promote a closed state of the receptor. However, the recent resting-state structure of GLIC reveals that the intrasubunit cavity is essentially unchanged (27). GAs binding to the TMD thus does not appear to be preferred in the GLIC resting state structure. Consistently, a recent study measuring the rate of modification by sulfhydryl-reactive reagents of cysteines introduced in the intrasubunit cavity in the presence or absence of propofol suggested that propofol stabilizes a distinct closed-state (62). This closed-state could be the desensitized state, as suggested by a recent radiolabelled-ligand competition study on the *Torpedo marmorata* nAChR, where propofol-binding was shown to stabilize the desensitized state of the channel and the mode of binding was found to involve a cavity similar to the intra-subunit one found in GLIC (63).

### 5.1.2 Intersubunit GA modulatory site

A recent structure-function study on the GLIC F14'A ethanol-sensitized variant shed light on the molecular basis of potentiation by GAs and alcohols (21). The absence of a phenyl ring in F14'A is sufficient to inverse the pharmacology of GLIC for GAs and alcohols. Indeed, while the pharmacology of the GLIC wild-type receptor for GAs and alcohols is similar to that of the nAChR (see above), the pharmacology of GLIC F14'A variant resembles that of the GlyRs and GABA<sub>A</sub>Rs; it is potentiated both by GAs (21, 57) and by ethanol at pharmacologically relevant concentrations (20 mM) (60). In the mutant structure, the inter-subunit cavity is expanded, penetrating one to two registers deeper into the membrane spanning region. The F14'A GLIC ethanol-sensitive variant was solved in the presence of ethanol, 2-bromo-ethanol and bromoform, which all bind in the expanded transmembrane cavity thus providing the first experimental description of ethanol bound to a pLGIC target (21) (Fig. 6). Co-crystallization with alcohols and GAs appeared to stabilize the GLIC F14'A structure, resulting in decreased B-factors in the transmembrane domain, consistent with a macroscopic role for these drugs in stabilizing the open state of the channel (21).

Site-directed mutagenesis of residues bordering the ethanol-binding pocket revealed that potentiation by ethanol relies on hydrophilic and hydrophobic contacts, while potentiation by bromoform is essentially mediated by hydrophobic contacts. Interestingly, a wealth of converging experimental evidences show that this cavity is conserved in human ethanol-sensitive pLGICs. The cavity identified in GLIC is consistent with specific amino-acid interactions previously shown to control allosteric modulation of both GlyRs (64) and GABA<sub>A</sub>Rs (65). In addition, photo-labelling experiments localized an etomidate (66) and a propofol (67) photo-reactive analogue binding-site at the transmembrane interfaces between subunits, overlapping the crystal structure site. Furthermore, the knowledge of the open and resting state structures of GLIC provides a structural rationale to the potentiating mechanism of ethanol. This potentiating site identified in the GLIC variant structure occupies a pivotal location for gating. It overlaps with a quaternary interaction between the M2 helix of one chain and the tip of the M1 helix of the neighbouring chain, a critical interaction for the ligand induced opening of the pore (27). Consistent with its potentiating effect, ethanol favours this quaternary interaction by simultaneously contacting the side chains of N15' and E19' in M2 and the main chain carbonyl oxygen of residue N200 in the tip of M1 (Fig. 6). Disrupting the interaction between ethanol and the side chain of residue N15' abolishes potentiation by ethanol (21). Interestingly, this residue aligns with the most critical residue for alcohol potentiation of GABA<sub>A</sub>Rs and GlyRs (68).

In addition, this potentiating site overlaps with the binding-site of ivermectin, which activates  $\alpha_1$ -Glu-Cl receptors (8). Similarly to ethanol in GLIC, ivermectin makes a critical hydrophilic contact with residue 15' (a serine in the case of Glu-Cl) (Fig. 6). Disruption of this contact was shown to abolish action of ivermectin in GABA<sub>A</sub>R (69) and GlyR (70). However, ivermectin binding also produces a local displacement of the M1 and M3 transmembrane helices, suggesting slightly different mechanisms for stabilizing the open state of pLGICs by the small (46 Da) ethanol and the relatively large (875 Da) ivermectin. In fact, one could hypothesize that ivermectin, through binding to this site, bypasses the ECD-TMD allosteric coupling regulated by the binding of a neurotransmitter to the orthosteric binding site. Overall, these data suggest that the transmembrane intersubunit interface hosts a potentiating modulatory site conserved from prokaryotic to eukaryotic pLGICs.

### 5.1.3 Ion channel GA binding site

Electrophysiology, mutagenesis and photoaffinity labelling and simulation have suggested that the hydrophobic region made of the top-half of the transmembrane pore might constitute a pharmacological relevant-site for pore block inhibition by GAs and alcohols. Recently, the co-crystal structure of ELIC with bromoform provided the first experimental evidence that anaesthetics such as bromoform and chloroform can bind in the hydrophobic portion of the pore (22) (Fig. 6), in line with computational studies that had previously revealed binding of isoflurane and propofol to the pore of GLIC (71). GAs could thus inhibit cationic pLGICs, whose pore is more hydrophobic than anionic pLGIC, by binding preferentially the transmembrane pore in its closed conformation rather than its open form.

## 5.2 Lipids

Lipids, free fatty acids and steroids (cholesterol) are known to allosterically modulate pLGICs (72, 73). The open GLIC structure shows electron density at the protein/lipid bilayer interface consistent with the presence of three lipid molecules per subunit (7). Because no exogenous lipids were added during the detergent solubilisation and protein purification, the observed molecules are most likely endogenous tightly-bound native lipids that were carried along throughout the sample preparation process from the original source. The intra-subunit phospholipid-binding site identified in the upper part of the TMD occupies a critical position for gating as it contacts simultaneously the tip of M1 and the Cys-loop via its polar head, two pivotal regions for the receptor's activation (27) (Fig. 6). Structural observations suggested that this phospholipid-binding site could be one of the molecular determinants that stabilize

the open form of the channel: it is displaced upon propofol binding (56) and destabilized in the GLIC locally-closed form as a consequence of rearrangement of side chain conformations in this region of the receptor (25). A very recent study has further documented the structural sensitivity of the GLIC receptor to its membrane environment (74). These binding sites thus constitute strong candidates for allosteric modulation by lipids.

### 5.3 Channel blockers

Open-channel pore blockers are non-competitive inhibitors that interfere with ion conduction when the channel is open but do not interfere with the agonist-mediated activation (75). The open-channel pore blockers encompass a structurally diverse class of molecules such as picrotoxine, tetraethylammonium (TEA), local anaesthetics (e.g. chlorpromazine, lidocaine and quinacrine), and some divalent transition metals. They often combine a positively charged amino group, corresponding to the net charge of the permeating ions in cationic-selective channels with a hydrophobic aromatic group and are thus too bulky to pass the channel constriction. Extensive affinity labelling with *Torpedo marmorata* nAChRs identified the bundle of M2 segments as constituting the binding sites for channel blockers (76, 77). Recently, X-ray structures of GLIC solved in the presence of a variety of open-pore channel blockers (18) and the picrotoxin-bound structure of Glu-Cl (8) clarify where channel blockers bind within the pore. Channel blockers bind at different locations between positions -2' and 9' within the pore and overlaps with critical regions identified for ion transport (Fig. 4B). Quaternary amines and lidocaine both bind within the transmembrane field near the 9' hydrophobic constriction and the 6' conserved ring of polar residues that was shown to host a water pentagon. In GluCl, picrotoxin binds to the cytosolic part of the pore between the -2' and 2' rings of residues that host preferential cation binding sites in Glu-Cl and GLIC. The divalent transition metal ion  $\text{Cd}^{2+}$  inhibits ions conduction by binding to the narrow intracellular end of the pore at a position that matches a preferred binding site of the permeant cation. Due to the sequence conservation in this region of the pore, these molecular mechanisms of channel block are likely to be conserved within the pLGIC family.

## 6. Conclusion and perspectives

Decades of pharmacological research have revealed that pLGIC are the targets of structurally diverse allosteric modulators that bind to topographically distinct sites. Modulation by GAs, alcohols, benzodiazepines and metal ions is thus the net effect of several competitive allosteric-binding sites. The expanding field of structural molecular biology of

pLGICs not only rationalises the mechanism of existing-drugs but identifies novel drugs binding sites, such as, for instance, the intrasubunit benzodiazepine binding-site identified in ELIC and the acetate binding sites found in GLIC. This review aimed to stress that the structures of all allosteric states of these receptors must be considered in order to understand the mechanisms of allosteric modulators. For example, the knowledge of three GLIC structures solved in distinct conformations (open, resting and locally closed) undoubtedly will help rationalize ligand-activation, as well as potentiation by GAs and alcohols. However, the quest for the structural determination of novel conformations continues. In addition to a basal closed-state and an active open-state, pLGICs exist in several desensitized states, as well as several intermediate states whose structure is still unknown. Obviously, it would be most interesting to determine the crystal structure of a desensitized form of GLIC. Furthermore, the structure determination of hetero-pentameric full-length mammalian pLGICs at atomic resolution is a goal of considerable importance that remains very challenging. Indeed, X-ray structures of integral pLGIC are limited, so far, to prokaryotic and lower-eukaryotic homo-pentameric receptors. The atomic structure determination of the additional cytoplasmic domain, which is absent in prokaryotic pLGICs but present in all eukaryotic pLGIC, will probably open the way to a largely unexplored territory for drug design. Expanding the detailed structural knowledge of pLGICs allosteric modulation paves the way towards a structure-based approach for drug-design that should impact positively the treatment of neurological disorders in the near future.

### **Acknowledgements**

We thank Pierre-Jean Corringer and Frederic Poitevin for helpful discussions and careful reading of this manuscript.

## References

1. Corringer PJ, *et al.* (2012) Structure and pharmacology of pentameric receptor channels: from bacteria to brain. *Structure* 20(6):941-956
2. Taly A, Corringer PJ, Guedin D, Lestage P, & Changeux JP (2009) Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. *Nat Rev Drug Discov* 8(9):733-750
3. Changeux JP (2013) The concept of allosteric modulation: an overview. *Drug Discov Today Technol* 10(2):e223-228
4. Unwin N (2005) Refined structure of the nicotinic acetylcholine receptor at 4Å resolution. *J Mol Biol* 346(4):967-989
5. Hilf RJ & Dutzler R (2008) X-ray structure of a prokaryotic pentameric ligand-gated ion channel. *Nature* 452(7185):375-379
6. Hilf RJ & Dutzler R (2009) Structure of a potentially open state of a proton-activated pentameric ligand-gated ion channel. *Nature* 457(7225):115-118
7. Bocquet N, *et al.* (2009) X-ray structure of a pentameric ligand-gated ion channel in an apparently open conformation. *Nature* 457(7225):111-114
8. Hibbs RE & Gouaux E (2011) Principles of activation and permeation in an anion-selective Cys-loop receptor. *Nature* 474(7349):54-60
9. Brejc K, *et al.* (2001) Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. *Nature* 411(6835):269-276
10. Dellisanti CD, Yao Y, Stroud JC, Wang ZZ, & Chen L (2007) Crystal structure of the extracellular domain of nAChR alpha1 bound to alpha-bungarotoxin at 1.94 Å resolution. *Nat Neurosci* 10(8):953-962
11. Li SX, *et al.* (2011) Ligand-binding domain of an alpha7-nicotinic receptor chimera and its complex with agonist. *Nat Neurosci* 14(10):1253-1259
12. Nemezc A & Taylor P (2011) Creating an alpha7 nicotinic acetylcholine recognition domain from the acetylcholine-binding protein: crystallographic and ligand selectivity analyses. *J Biol Chem* 286(49):42555-42565
13. Nury H, *et al.* (2010) Crystal structure of the extracellular domain of a bacterial ligand-gated ion channel. *J Mol Biol* 395(5):1114-1127
14. Chasapis CT, Argyriou AI, Corringer PJ, Bentrop D, & Spyroulias GA (2011) Unravelling the conformational plasticity of the extracellular domain of a prokaryotic nAChR homologue in solution by NMR. *Biochemistry* 50(45):9681-9683
15. Cui T, *et al.* (2012) NMR structure and dynamics of a designed water-soluble transmembrane domain of nicotinic acetylcholine receptor. *Biochim Biophys Acta* 1818(3):617-626
16. Mowrey DD, *et al.* (2013) Open-channel structures of the human glycine receptor alpha1 full-length transmembrane domain. *Structure* 21(10):1897-1904
17. Sauguet L, *et al.* (2013) Structural basis for ion permeation mechanism in pentameric ligand-gated ion channels. *EMBO J* 32(5):728-741

18. Hilf RJ, *et al.* (2010) Structural basis of open channel block in a prokaryotic pentameric ligand-gated ion channel. *Nat Struct Mol Biol* 17(11):1330-1336
19. Zimmermann I, Marabelli A, Bertozzi C, Sivilotti LG, & Dutzler R (2012) Inhibition of the prokaryotic pentameric ligand-gated ion channel ELIC by divalent cations. *PLoS Biol* 10(11):e1001429
20. Spurny R, *et al.* (2012) Pentameric ligand-gated ion channel ELIC is activated by GABA and modulated by benzodiazepines. *Proc Natl Acad Sci U S A* 109(44):E3028-3034
21. Sauguet L, *et al.* (2013) Structural basis for potentiation by alcohols and anaesthetics in a ligand-gated ion channel. *Nat Commun* 4:1697
22. Spurny R, *et al.* (2013) Multisite binding of a general anesthetic to the prokaryotic pentameric *Erwinia chrysanthemi* ligand-gated ion channel (ELIC). *J Biol Chem* 288(12):8355-8364
23. Nury H, *et al.* (2010) One-microsecond molecular dynamics simulation of channel gating in a nicotinic receptor homologue. *Proc Natl Acad Sci U S A* 107(14):6275-6280
24. Calimet N, *et al.* (2013) From the Cover: A gating mechanism of pentameric ligand-gated ion channels. *Proc Natl Acad Sci U S A* 110(42):E3987-3996
25. Prevost MS, *et al.* (2012) A locally closed conformation of a bacterial pentameric proton-gated ion channel. *Nat Struct Mol Biol* 19(6):642-649
26. Gonzalez-Gutierrez G, Cuello LG, Nair SK, & Grosman C (2013) Gating of the proton-gated ion channel from *Gloeobacter violaceus* at pH 4 as revealed by X-ray crystallography. *Proc Natl Acad Sci U S A*
27. Sauguet L, *et al.* (2013) Crystal structures of a pentameric ligand-gated ion channel provide a mechanism for activation. *Proc Natl Acad Sci U S A*
28. Parikh RB, Bali M, & Akabas MH (2011) Structure of the M2 transmembrane segment of GLIC, a prokaryotic Cys loop receptor homologue from *Gloeobacter violaceus*, probed by substituted cysteine accessibility. *J Biol Chem* 286(16):14098-14109
29. Velisetty P & Chakrapani S (2012) Desensitization mechanism in prokaryotic ligand-gated ion channel. *J Biol Chem* 287(22):18467-18477
30. Velisetty P, Chalamalasetti SV, & Chakrapani S (2012) Conformational transitions underlying pore opening and desensitization in membrane-embedded *Gloeobacter violaceus* ligand-gated ion channel (GLIC). *J Biol Chem* 287(44):36864-36872
31. Giraudat J, Dennis M, Heidmann T, Chang JY, & Changeux JP (1986) Structure of the high-affinity binding site for noncompetitive blockers of the acetylcholine receptor: serine-262 of the delta subunit is labeled by [3H]chlorpromazine. *Proc Natl Acad Sci U S A* 83(8):2719-2723
32. Hucho F, Oberthur W, & Lottspeich F (1986) The ion channel of the nicotinic acetylcholine receptor is formed by the homologous helices M II of the receptor subunits. *FEBS Lett* 205(1):137-142
33. Imoto K, *et al.* (1986) Location of a delta-subunit region determining ion transport through the acetylcholine receptor channel. *Nature* 324(6098):670-674
34. Imoto K, *et al.* (1988) Rings of negatively charged amino acids determine the acetylcholine receptor channel conductance. *Nature* 335(6191):645-648

35. Keramidas A, Moorhouse AJ, Schofield PR, & Barry PH (2004) Ligand-gated ion channels: mechanisms underlying ion selectivity. *Prog Biophys Mol Biol* 86(2):161-204
36. Katz B & Miledi R (1966) Input-output relation of a single synapse. *Nature* 212(5067):1242-1245
37. Colquhoun D & Sakmann B (1998) From muscle endplate to brain synapses: a short history of synapses and agonist-activated ion channels. *Neuron* 20(3):381-387
38. Corringer PJ, *et al.* (1999) Mutational analysis of the charge selectivity filter of the alpha7 nicotinic acetylcholine receptor. *Neuron* 22(4):831-843
39. Konno T, *et al.* (1991) Rings of anionic amino acids as structural determinants of ion selectivity in the acetylcholine receptor channel. *Proc Biol Sci* 244(1310):69-79
40. Duret G, *et al.* (2011) Functional prokaryotic-eukaryotic chimera from the pentameric ligand-gated ion channel family. *Proc Natl Acad Sci U S A* 108(29):12143-12148
41. Corringer PJ, Le Novere N, & Changeux JP (2000) Nicotinic receptors at the amino acid level. *Annu Rev Pharmacol Toxicol* 40:431-458
42. Pan J, *et al.* (2012) Structure of the pentameric ligand-gated ion channel ELIC cocrystallized with its competitive antagonist acetylcholine. *Nat Commun* 3:714
43. Nys M, Kesters D, & Ulens C (2013) Structural insights into Cys-loop receptor function and ligand recognition. *Biochem Pharmacol* 86(8):1042-1053
44. Brams M, *et al.* (2011) A structural and mutagenic blueprint for molecular recognition of strychnine and d-tubocurarine by different cys-loop receptors. *PLoS Biol* 9(3):e1001034
45. Sigel E & Steinmann ME (2012) Structure, function, and modulation of GABA(A) receptors. *J Biol Chem* 287(48):40224-40231
46. Ramerstorfer J, *et al.* (2011) The GABAA receptor alpha+beta- interface: a novel target for subtype selective drugs. *J Neurosci* 31(3):870-877
47. Mulle C, Lena C, & Changeux JP (1992) Potentiation of nicotinic receptor response by external calcium in rat central neurons. *Neuron* 8(5):937-945
48. Vernino S, Amador M, Luetje CW, Patrick J, & Dani JA (1992) Calcium modulation and high calcium permeability of neuronal nicotinic acetylcholine receptors. *Neuron* 8(1):127-134
49. Peters JA, Hales TG, & Lambert JJ (1988) Divalent cations modulate 5-HT3 receptor-induced currents in N1E-115 neuroblastoma cells. *Eur J Pharmacol* 151(3):491-495
50. Palma E, Maggi L, Miledi R, & Eusebi F (1998) Effects of Zn<sup>2+</sup> on wild and mutant neuronal alpha7 nicotinic receptors. *Proc Natl Acad Sci U S A* 95(17):10246-10250
51. Laube B, *et al.* (1995) Modulation by zinc ions of native rat and recombinant human inhibitory glycine receptors. *J Physiol* 483 ( Pt 3):613-619
52. Prevost MS, *et al.* (2013) Identification of cinnamic acid derivatives as novel antagonists of the prokaryotic proton-gated ion channel GLIC. *J Med Chem* 56(11):4619-4630
53. Hamouda AK, Jayakar SS, Chiara DC, & Cohen JB (2013) Photoaffinity Labeling of Nicotinic Receptors: Diversity of Drug Binding Sites! *J Mol Neurosci*
54. Olsen RW, *et al.* (2013) Structural Models of Ligand-Gated Ion Channels: Sites of Action for Anesthetics and Ethanol. *Alcohol Clin Exp Res*



55. Howard RJ, *et al.* (2011) Alcohol-binding sites in distinct brain proteins: the quest for atomic level resolution. *Alcohol Clin Exp Res* 35(9):1561-1573
56. Nury H, *et al.* (2011) X-ray structures of general anaesthetics bound to a pentameric ligand-gated ion channel. *Nature* 469(7330):428-431
57. Bromstrup T, Howard RJ, Trudell JR, Harris RA, & Lindahl E (2013) Inhibition versus potentiation of ligand-gated ion channels can be altered by a single mutation that moves ligands between intra- and intersubunit sites. *Structure* 21(8):1307-1316
58. Changeux JP (2012) Conscious processing: implications for general anesthesia. *Curr Opin Anaesthesiol* 25(4):397-404
59. Weng Y, Yang L, Corringier PJ, & Sonner JM (2010) Anesthetic sensitivity of the *Gloeobacter violaceus* proton-gated ion channel. *Anesth Analg* 110(1):59-63
60. Howard RJ, *et al.* (2011) Structural basis for alcohol modulation of a pentameric ligand-gated ion channel. *Proc Natl Acad Sci U S A* 108(29):12149-12154
61. Jayakar SS, Dailey WP, Eckenhoff RG, & Cohen JB (2013) Identification of propofol binding sites in a nicotinic acetylcholine receptor with a photoreactive propofol analog. *J Biol Chem* 288(9):6178-6189
62. Ghosh B, Satyshur KA, & Czajkowski C (2013) Propofol binding to the resting state of the *gloeobacter violaceus* ligand-gated ion channel (GLIC) induces structural changes in the inter- and intrasubunit transmembrane domain (TMD) cavities. *J Biol Chem* 288(24):17420-17431
63. Jayakar SS, Dailey WP, Eckenhoff RG, & Cohen JB (2013) Identification of Propofol Binding Sites in a Nicotinic Acetylcholine Receptor with a Photoreactive Propofol Analog. *J Biol Chem*
64. Borghese CM, *et al.* (2012) Characterization of two mutations, M287L and Q266I, in the alpha1 glycine receptor subunit that modify sensitivity to alcohols. *J Pharmacol Exp Ther* 340(2):304-316
65. Borghese C, Hicks JA, Lapid DJ, Trudell JR, & Harris RA (2013) GABA receptor transmembrane amino acids are critical for alcohol action: disulfide crosslinking and alkyl methanethiosulfonate labeling reveal relative location of binding sites. *J Neurochem*
66. Li GD, *et al.* (2006) Identification of a GABAA receptor anesthetic binding site at subunit interfaces by photolabeling with an etomidate analog. *J Neurosci* 26(45):11599-11605
67. Yip GM, *et al.* (2013) A propofol binding site on mammalian GABAA receptors identified by photolabeling. *Nat Chem Biol* 9(11):715-720
68. Mihic SJ, *et al.* (1997) Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors. *Nature* 389(6649):385-389
69. Adelsberger H, Lepier A, & Dudel J (2000) Activation of rat recombinant alpha(1)beta(2)gamma(2S) GABA(A) receptor by the insecticide ivermectin. *Eur J Pharmacol* 394(2-3):163-170
70. Shan Q, Haddrill JL, & Lynch JW (2001) Ivermectin, an unconventional agonist of the glycine receptor chloride channel. *J Biol Chem* 276(16):12556-12564
71. LeBard DN, Henin J, Eckenhoff RG, Klein ML, & Brannigan G (2012) General anesthetics predicted to block the GLIC pore with micromolar affinity. *PLoS Comput Biol* 8(5):e1002532

72. Baenziger JE & Corringer PJ (2011) 3D structure and allosteric modulation of the transmembrane domain of pentameric ligand-gated ion channels. *Neuropharmacology* 60(1):116-125
73. daCosta CJ, Dey L, Therien JP, & Baenziger JE (2013) A distinct mechanism for activating uncoupled nicotinic acetylcholine receptors. *Nat Chem Biol* 9(11):701-707
74. Labriola JM, *et al.* (2013) Structural sensitivity of a prokaryotic pentameric ligand-gated ion channel to its membrane environment. *J Biol Chem* 288(16):11294-11303
75. Hille B (2001) *Ion Channels of Excitable Membranes* 3rd edition. (Sinauer Associates Inc., Sunderland, Massachusetts, USA).
76. Revah F, *et al.* (1990) The noncompetitive blocker [3H]chlorpromazine labels three amino acids of the acetylcholine receptor gamma subunit: implications for the alpha-helical organization of regions MII and for the structure of the ion channel. *Proc Natl Acad Sci U S A* 87(12):4675-4679
77. Karlin A (2002) Emerging structure of the nicotinic acetylcholine receptors. *Nat Rev Neurosci* 3(2):102-114

## Figure legends

**Figure 1: Allosteric modulatory sites in pLGICs.** (A) Allosteric scheme for pLGICs implicating resting (yellow), active (blue) and desensitized (purple) states. Allosteric modulatory sites are white when empty and coloured when bound to the ligand. The dashed line indicates that in some particular cases, antagonists stabilize the desensitized state of the receptor. (B) Cartoon representation of the GLIC receptor viewed from the side superimposed onto a selection of ligand-binding sites. Ligands are shown as sticks. Several topographically distinct modulation sites, distributed either in the ECD or the TMD, are represented in the stick mode, or as spheres.

**Figure 2: A selection of ions and ligand analogues displaying anomalous diffusion properties that were used in order to confirm ligand-binding sites in pLGIC structures.** (A) Chemical structures of the ligand analogues where the atoms displaying anomalous diffusion properties are highlighted in blue. (B) A representative example of the usefulness of the anomalous diffusion signal. The bromine-specific anomalous signal (shown as a blue mesh contoured at a level of  $5\sigma$ ) helps orienting a molecule of 2-bromo-ethanol in the 2mFo-DFc electron density (shown as a grey mesh contoured at a level of  $1\sigma$ ).

**Figure 3: Allosteric transitions in pLGICs.** (A) Comparison of the GLIC resting-state (yellow), GLIC open (blue), and ELIC (pink) ECD structures. This cartoon representation is viewed from the top of ECD. A circle schematically represents the location of the interfacial orthosteric agonist-binding site. The agonist-binding sites are white when unbound and coloured pink when bound. The quaternary twist and shrink motions are indicated with black arrows. (B) Superimposition of the GLIC resting-state (yellow), GLIC open (blue) and ELIC (pink) TMD structures. This cartoon representation is viewed from the top of TMD. The side chains of the 9' and 13' pore-lining residues are shown as spheres. (C) Enlarged views of the pore. The solvent-accessible region is shown by a green mesh. The side chains of the pore-lining residues are shown as sticks. Polar and hydrophobic residues are respectively coloured in green and yellow. (D) The M2 and M3 helices in different conformations of GLIC open, GLIC closed and ELIC structures. The top panels display a schematic representation of the M2-M3 helices viewed from the side.


**Figure 4: The interior of GLIC open-pore structure** (A) Enlarged representation of the pore with the M2 helices shown as a cartoon. The side chains of the pore-lining residues are shown as sticks. Cation (blue), anion (red) preferred binding sites in the GLIC open-pore structure are shown as spheres. Structurally ordered water molecules observed experimentally are shown in pink. Water binding-sites predicted by MD simulations are shown in orange. The alternative conformation that is adopted by Glu-2' is also represented (yellow) (B) Distribution of channel blockers in the pore of pLGICs.

**Figure 5: Structural basis for ligand binding in AChBP versus ligand-activation in pLGICs.** (A) Conserved cation- $\pi$  interactions in AChBPs and pLGICs. (Left panel) Nicotine in agonist binding pocket of Ls AChBP (1UW6). (Right panel) GABA in the agonist binding pocket of ELIC (2YOE). The principal side of the ligand binding site is displayed in light grey, the complementary side in dark grey. The side chains of the residues that contribute to cation- $\pi$  interactions are indicated in brown. (B) (Top-left panel) Comparison of the epibatidine-bound (agonist; 2BYQ) and  $\alpha$ -conotoxin bound (antagonist; 2BYP) structures of the *Aplysia californica* AChBP viewed from the top (coloured in green and red, respectively). Curved lines illustrate the principal (+) and complementary (-) sides of the orthosteric site. Loop C are shown as tubes. (Top-right panel) Same view, but showing the comparison between the open and resting state GLIC structures (coloured in blue and yellow, respectively). The quaternary twist and shrinking motions are indicated with black arrows. Bottom panels show enlarged views of the orthosteric agonist-binding site at the interface between neighbouring subunits.

**Figure 6: Transmembrane pharmacology in pLGIC.** (Central panels): TMD of the open state and resting state GLIC structures viewed from the top. The inter subunit, intrasubunit and channel modulatory sites are shown in green, pink and orange, respectively. (Left panels): Enlarged view of the ethanol-bound GLIC and ivermectine-bound GluCl structures (in blue) superimposed onto the GLIC resting-state closed structure (yellow). The receptors are represented as cartoons, the side chains and the ligands as sticks. In both cases, ligand binding promotes the open form of the receptor by favouring the quaternary interaction between the tip of M1 and M2. (Top-right panel): Enlarged view of the intrasubunit site showing the superimposition of the propofol (light pink), desflurane (magenta) and bromoform (red) binding sites. The phospholipid that faces the transmembrane entrance of the cavity is also


represented (green). (Bottom-right panel): The bromoform pore binding-site as observed in ELIC.

**Table 1: A selection of ligand-bound pLGIC X-ray structures, indicating the resolution of the diffraction data and the PDB code of the corresponding structure.**




**Figure 1**


**A**




ions




tetraethyl-arsonium



bromo-flurazepam




bromo-lidocaine



bromoform

**B**



2-bromo-ethanol






Figure 2




**Figure 3**






**Figure 4**

**A**




**Nicotine-bound Ls-AChBP**




**GABA-bound ELIC**

**B**

**Ligand-binding in AChBP**



**Ligand activation in pLGIC**



**Figure 5**




Figure 6

	<b>PDBid</b>	<b>Protein</b>	<b>Ligand</b>	<b>Resolution</b>	<b>Reference</b>
<b>Agonists</b>	2YOE	ELIC	GABA	3.9 Å	[20]
	3RIF	Glu-Cl	Glutamate	3.35 Å	[8]
<b>Antagonists</b>	3RQW	ELIC	Acetylcholine	2.9 Å	[42]
<b>Benzodiazepines</b>	2YOE	ELIC	Flurazepam	3.9 Å	[20]
	4A98	ELIC	Br-Flurazepam	3.6 Å	[20]
	4A97	ELIC	Zopiclone	3.34 Å	[20]
<b>General Anaesthetics</b>	3P50	GLIC	Propofol	3.3 Å	[56]
	3P4W	GLIC	Desflurane	3.1 Å	[56]
	4HFD	GLIC	Bromoform	3.1 Å	[21]
		F14'A			
	4HFB	GLIC	Bromoform	2.65 Å	[21]
	3ZKR	ELIC	Bromoform	3.65 Å	[22]
<b>Alcohols</b>	4HFE	GLIC	Ethanol	2.8 Å	[21]
		F14'A			
	4HFC	GLIC	2-bromo-ethanol	3.05 Å	[21]
		F14'A			
<b>Ivermectine</b>	3RHW	Glu-Cl	ivermectine	3.1 Å	[8]
<b>Channel Blockers</b>	2XQ5	GLIC	Tetra-ethyl-arsonium	3.5 Å	[18]
	2XQA	GLIC	Tetra-butyl-antimony	3.7 Å	[18]
	2XQ4	GLIC	Tetra-methyl-arsonium	3.6 Å	[18]
	2XQ3	GLIC	Bromo-lidocaine	3.5 Å	[18]
	3RI5	Glu-Cl	Picrotoxine	3.4 Å	[8]
<b>Divalent ions</b>	2YN6	ELIC	Ba <sup>++</sup>	3.3 Å	[19]
	2XQ8	GLIC	Zn <sup>++</sup>	3.6 Å	[18]

**Table 1**